This is a multicenter, long-term study of sirukumab (CNTO 136) that will be conducted in two groups of participants at the same time (parallel-group study). The maximum duration of participation in this study is 208 weeks, followed by approximately 16 weeks of safety and efficacy follow-up after the administration of the final study agent injection of sirukumab. Participant safety will be monitored throughout the study.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01856309?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
